This page respects the original work's rights terms and independently introduces its bibliography, abstract, main results, and limitations. It is not a full translation.
About this resource
This page provides a detailed introduction to an observational study that followed people with opioid dependence for 12 months after legally receiving ibogaine treatment in New Zealand, using information available from the structured PubMed abstract and public bibliographic records. It is not a translation of the publisher’s full text, and it does not speculate about doses, treatment procedures, the detailed circumstances of the death, or follow-up tables absent from the abstract.
An important feature of this study is that the abstract explicitly reports not only changes in long-term measures but also the death of one enrollee during treatment. The direction of improvement and this major safety signal must be read together. The abstract alone, however, cannot determine the cause of death or its causal relationship to ibogaine. This resource does not provide diagnosis, treatment selection, or administration instructions.
Study design
The study enrolled 14 people, 50% of whom were women. Participants received a single ibogaine treatment from one of two treatment providers and were then observed for 12 months. The principal outcome was addiction-related severity on the Addiction Severity Index-Lite (ASI-Lite); depressive symptoms were assessed secondarily with the Beck Depression Inventory-II (BDI-II). Acute opioid withdrawal symptoms were evaluated with the Subjective Opioid Withdrawal Scale (SOWS), collected before and immediately after treatment.
Eight participants completed every interview from baseline through 12 months. Nonparametric comparisons using the Friedman test were conducted among these completers. Four participants had partial data, and the abstract summarizes their results separately. One enrollee died during treatment. The public abstract does not explain the follow-up status of the remaining one person among the 14 enrolled.
Content
As background, the authors state that ibogaine’s legal status in New Zealand created an opportunity to observe how long outcomes after treatment might persist. The purpose was to examine longitudinal outcomes over 12 months among people with opioid dependence who legally received ibogaine treatment.
For the directly reported acute result, SOWS scores decreased significantly from before to immediately after treatment in all 14 participants, with p = 0.015. The abstract does not provide mean scores or the amount of change, so its magnitude and clinical meaning cannot be assessed from this information alone. SOWS is also a subjective withdrawal scale, and no comparison group was used.
Among the eight people who completed all interviews through 12 months, the ASI-Lite drug-use composite score decreased significantly from baseline to 12 months, with p = 0.002. BDI-II scores also decreased, with p < 0.001. The abstract states that the four participants with partial data also showed directional reductions in ASI-Lite drug-use scores and problems in family/social status, but it does not give participant-level values or measurement times.
The authors concluded that a single treatment reduced withdrawal symptoms and led to cessation or sustained reduction of opioid use over 12 months. They also interpreted legal availability as potentially improving outcomes by allowing treatment providers to collaborate closely with other health professionals. The direct data in the public abstract, however, consist of scale scores and p values; it does not state how many people ceased use, monthly quantities used, or objective drug-test results. These findings therefore cannot be converted into an individual abstinence rate or a causal effect.
Results
The confirmed observations are a decrease in acute SOWS scores among 14 participants; lower ASI-Lite drug-use and BDI-II scores at 12 months than at baseline among the eight completers; improvement in some domains among four participants with partial data; and the death of one enrollee during treatment.
The study did not establish comparison with another treatment, general efficacy, which participants stopped or reduced use, an objectively confirmed 12-month abstinence rate, relapse prevention, or safe conditions of administration. Statistical significance in a small observational sample does not by itself demonstrate treatment efficacy or clinical usefulness.
Limitations
This was a very small sample of 14 enrollees and 8 twelve-month completers, without randomization, blinding, or a control group. Selection by participants and treatment providers, expectations, post-treatment medical and social support, and natural history cannot be separated from the effects of ibogaine alone. Procedures may also have differed between the two providers, but the abstract provides neither protocols nor a comparison.
A completer analysis may be affected by attrition bias. The abstract cannot establish whether people in better condition were more likely to remain in follow-up, or the reverse. ASI-Lite, BDI-II, and SOWS are standardized measures but include self-report components, and the abstract does not state that drug use was continuously verified objectively. It also does not provide specific values for the four people with partial data, the status of the remaining enrollee, or methods for handling missing data. Because of these uncertainties, the authors’ long-term conclusion should be treated as hypothesis-generating.
Safety
The abstract explicitly states that one enrollee died during treatment. This is a major observed fact that cannot be disregarded. At the same time, the abstract does not provide cause of death, timeline, comorbidities, concomitant medications, dose, monitoring method, autopsy findings, or the investigators’ causality assessment. This resource therefore cannot conclude either that ibogaine caused the death or that it was unrelated.
The public abstract also does not report other adverse events, ECG changes, total serious adverse events, or exclusion criteria. Decreases in withdrawal or mood scores cannot substitute for a safety assessment, and the study does not yield a safe dose or implementation conditions. Its results do not support individual use or treatment without monitoring.
Source and rights
Bibliographic information and the structured abstract are available through PubMed, and the original article is identified by its DOI. The DOI metadata registered by the publisher with Crossref identifies the version of record as Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 (CC BY-NC-ND 4.0). This page is an independent detailed introduction based only on the public abstract and metadata, not a translation of the publisher’s full text.